新利18体育,18新利体育网页登录入口,18新利

Current Location:homepage  informations  doctordoctor

QIAN, HAI

Time:2017-12-30   Browse times:480

Hai Qian, Ph D, Professor. Received his Bachelor degree from the college of pharmacy, Shandong University in 2001 and his Ph.D. in medicinal chemistry at the China Pharmaceutical University in 2007. Is currently a Professor of Center of Drug Discovery, State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, China Pharmaceutical University. Major research interests are involved in the design, bioactivities and structure-activity relationship studies of small molecule or peptide for type II diabetes, antitumor and multidrug resistance. Got the Chinese Pharmaceutical Association-SERVIER Young Investigator Awards in Medicinal Chemistry in 2010. And is one of the third level awardees of Jiangsu province 333 high-level personnel training project. Has published more than 70 papers in the last five years. Participates in application of 29 Chinese patents and 2 international patents, 13 of them are authorized.

  

Research Project:

Principle Investigator sponsored by the Project of National Natural Science Foundation (No. 81273376), Key Project of Chinese Ministry of Education (No.109086), Ph.D. Programs Foundation of Ministry of Education of China and Youth Project of Natural Science Foundation of Jiangsu (No. BK2012356). Participates in three general programs of the Project of National Natural Science Foundation, and studies on pre-clinical and candidate drugs of the National Key Project for Development of New Drugs.

  

Typical Published Papers (*corresponding author):

1. Zheng Li, XueXu, Wenlong Huang*, Hai Qian*. Free Fatty Acid Receptor 1 (FFAR1) As an Emerging Therapeutic Target for Type 2 Diabetes Mellitus: Recent Progress and Prevailing Challenges. Medicinal Research Reviews, 2017, DOI:10.1002/med.21441. (IF=8.79 )

2. Qianqian Qiu, Baomin Liu, Jian Cui, Zheng Li, Xin Deng, HaoQiang, Jieming Li, Chen Liao, Bo Zhang, Wei Shi, Miaobo Pan, Wenlong Huang* and Hai Qian*, Design, Synthesis, and Pharmacological Characterization of N-(4-(2 (6, 7-Dimethoxy-3, 4-dihydroisoquinolin-2 (1-H)-yl)-ethyl)-phenyl)-quinazolin-4-amine Derivatives: Novel Inhibitors Reversing P-Glycoprotein-Mediated Multidrug Resistance. Journal of Medicinal Chemistry, 2017, 60(8): 3289-3302. (IF=6.259 )

3. Qianqian Qiu, Wei Shi, Zheng Li, Bo Zhang, Miaobo Pan, Jian Cui, Yuxuan Dai, Wenlong Huang* and Hai Qian*, Exploration of 2-((Pyridin-4-ylmethyl) amino) nicotinamide Derivatives as Potent Reversal Agents against P-Glycoprotein-Mediated Multidrug Resistance. Journal of Medicinal Chemistry, 2017, 60(7): 2930-2943. (IF=6.259)

4. Xue Li, Mian Fu, Jun Wu*, Chenyu Zhang, Xin Deng, ArvindDhinakar, Wenlong Huang, HaiQian*, Liang Ge*, pH-sensitive peptide hydrogel for glucose-responsive insulin delivery. Acta Biomaterialia, 2017, 51: 294-303. (IF=6.319)

5. Zheng Li, Qianqian Qiu, Xue Xu, Xuekun Wang, Lei Jiao, Xin Su, Miaobo Pan, Wenlong Huang*, Hai Qian*, Design, synthesis and Structure-activity relationship studies of new thiazole-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes, European Journal of Medicinal Chemistry, 2016 , 113(20), 246-257. (IF=4.519)

6. Xin Deng, Qianqian Qiu, Baowei Yang, Xuekun Wang, Wenlong Huang*, Hai Qian*. Design, synthesis and biological evaluation of novel peptides with anti-cancer and drug resistance-reversing activities. European Journal of Medicinal Chemistry, 2015, 89(1), 540-548. (IF=4.519)

7. Jing Han, Lidan Sun, Xun Huang, Zheng Li, Chenyu Zhang, Hai Qian* and  Wenlong Huang*.  Novel coumarin modified GLP-1 derivatives with enhanced plasma stability and prolonged in vivo glucose-lowering ability. British Journal of Pharmacology2014171 (23) 5252–5264. (IF=5.49)

8. Baowei Yang, Yicheng Mei, Xuekun Wang, Xin Deng, Hai Qian*, Wenlong Huang*. Design, synthesis and biological evaluation of novel peptide MC62 analogues as potential antihyperglycemic agents. European Journal of Medicinal Chemistry, 2014, (73),105-111. (IF=4.519)

9. Jing Han, Lidan Sun, Yingying Chu, Zheng Li, Dandan Huang, Xiaoyun Zhu, Hai Qian*, Wenlong Huang*. Design, Synthesis and Biological activity studies of Novel Dicoumarin-Glucagon-Like Peptide-1 Conjugates. Journal of Medicinal Chemistry, 201356(24), 9955-9968. (IF=6.259)

10. Jing Han, Xun Huang, Lidan Sun, Zheng Li, Hai Qian*, Wenlong Huang*, Novel fatty chain-modified glucagon-like peptide-1 conjugates with enhanced stability and prolonged in vivo activity. Biochemical Pharmacology, 2013, 86(2), 297-308. (IF=4.58)

  

Contact Information:

Center of Drug Discovery, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, Jiangsu, 210009, P. R. China

Phone: +86-25-83271051

E-mail: qianhai24@163.com or qianhai24@cpu.edu.cn 


新利18体育_18新利体育网页登录入口_18新利